Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Kiniksa Pharmaceuticals Ltd is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 168 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $10.90 |
|---|---|
| 52-week range | $9.96 - $24.70 |
| 50-day moving average | $12.10 |
| 200-day moving average | $13.15 |
| Wall St. target price | $28.60 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.56 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.9 from 2022-01-25
| 1 week (2022-01-19) | -1.62% |
|---|---|
| 1 month (2021-12-23) | -17.05% |
| 3 months (2021-10-26) | 2.83% |
| 6 months (2021-07-26) | -22.97% |
| 1 year (2021-01-26) | -44.73% |
|---|---|
| 2 years (2020-01-24) | -25.44% |
| 3 years (2019-01-25) | 22.37 |
| 5 years (2017-01-22) | N/A |
| Revenue TTM | $19.8 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -34.01% |
| Return on equity TTM | -61.22% |
| Profit margin | 0% |
| Book value | $3.11 |
| Market capitalisation | $750.9 million |
TTM: trailing 12 months
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $9.96 up to $24.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is -0.0986. This would suggest that Kiniksa Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kiniksa Pharmaceuticals has bucked the trend.
Kiniksa Pharmaceuticals, Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.